

Name of trial	Outline of trial	Eligible CLL/SLL population	Centres open	In set up	Treatment	Website for more information	Email
BGB-11417-301 (Celestial)	Sonrotoclax +Zanubrutinib vs Venetoclax+Obinutuzimab	Treatment naïve & needing treatment	Wellington; Christchurch; Tauranga; North Shore	Dunedin	A Phase 3, Randomized Study	https://clinicaltrials.gov/study/NCT06073821	clinicaltrials@beigene.com
Name of trial	Outline of trial	Eligible CLL/SLL population	Centres open	In set up	Treatment	Website for more information	Email
BGB-11417-101	BCL2 Inhibitor BGB-11417 (Sonrotoclax); w or wo zanubrutinib	Treatment naïve; or relapse/refractory; needing treatment	Wellington; North Shore; ADHB	n/a	A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Sonrotoclax and Zanubrutinib	https://clinicaltrials.gov/study/NCT04277637	clinicaltrials@beigene.com
Name of trial	Outline of trial	Eligible CLL/SLL population	Centres open	In set up	Treatment	Website for more information	Email
LOXO-BTK-20030	Pirtobrutinib (LOXO-305) versus Ibrutinib	All patients needing treatment	Waikato; Middlemore; Southern	n/a	A Phase 3, Randomized Study	https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=20969&isClinicalTrial=True	info@anzctr.org.au
Name of trial	Outline of trial	Eligible CLL/SLL population	Centres open	In set up	Treatment	Website for more information	Email
Abbvie M14-728	Venteoclax for Relapse/refractory p53 CLL	Relapse/refractory p53 CLL needing treatment	Christchurch	n/a	Participants with 17p deletion status will receive various doses of venetoclax once daily	https://clinicaltrials.gov/study/NCT02966756	abbvieclinicaltrials@abbvie.com

Trials in set up							
Bellwave 01	Nemtabrutinib Versus	Treatment naïve	North Shore		A Phase 3, Randomized Study		
	Investigator's Choice of Ibrutinib or Acalabrutinib	needing treatment	Middlemore				